Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
11:46am, Tuesday, 30'th Sep 2025
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
DEADLINE ALERT for NVO and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
11:16am, Tuesday, 30'th Sep 2025
LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R.
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 30'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
10:35am, Tuesday, 30'th Sep 2025
NEW YORK--(BUSINESS WIRE)---- $NVO #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo” or the “Company�
The Truth About Novo Nordisk: 4 Myths That Don't Hold Up
09:30am, Tuesday, 30'th Sep 2025
Novo Nordisk remains a strong buy despite recent market pessimism, with key growth catalysts on the horizon. NVO's Wegovy, especially at higher doses, rivals Eli Lilly's Zepbound in weight loss and of
LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers
08:14am, Tuesday, 30'th Sep 2025
Telehealth firm LifeMD said on Tuesday it would collaborate with Novo Nordisk to offer its diabetes drug Ozempic at $499 per month to eligible U.S. patients, including those who are insured and whose
Why Is Novo Nordisk Stock Down in 2025, and Is It a Buying Opportunity?
06:30am, Tuesday, 30'th Sep 2025
Novo Nordisk (NVO -0.16%) stock investors are eagerly awaiting the potential launch of its weight loss treatment in oral form.
Why Novo Nordisk Stock Slumped on Monday
06:05pm, Monday, 29'th Sep 2025
Drug tariffs, tough competition, and a fresh analyst recommendation downgrade were the burdens pulling down Novo Nordisk (NVO -0.16%) stock on Monday. In some respects, then, it was surprising that th
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
04:28pm, Monday, 29'th Sep 2025
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 202
Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join – Contact The Gross Law Firm
04:15pm, Monday, 29'th Sep 2025
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28,
Here's Why Morgan Stanley Analysts Downgraded Novo Nordisk's Stock
02:35pm, Monday, 29'th Sep 2025
An analyst's concerns about demand for Novo Nordisk's blockbuster weight-loss drugs is weighing on the drugmaker's shares to start the week.
Portnoy Law Firm Announces Class Action on Behalf of Novo Nordisk A/S Investors
01:39pm, Monday, 29'th Sep 2025
LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S, ("Novo" or the "Company") (NYSE: NVO) investors of a class action on behalf of investors that bought secu
NVO Slides on Morgan Stanley Downgrade, Case for Value Trade
12:00pm, Monday, 29'th Sep 2025
Morgan Stanley now holds the most pessimistic view of Novo Nordisk's (NVO) stock. It downgraded the company to underweight from equal weight and set a Street-low price target of $47.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 30, 2025 deadline to participate as a lead plaintiff in the securities fraud class action law
